Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (41)
  • Allergen immunotherapy (81)
  • AllergoOncology (15)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (235)
  • Allied health and primary care (20)
  • Anaphylaxis (113)
  • Artificial Intelligence (12)
  • Asthma (185)
  • Basic immunology (58)
  • Biologicals (90)
  • Biomarkers (64)
  • Comparative veterinary allergology (1)
  • COVID19 (11)
  • Dermatology (125)
  • Drug allergy (172)
  • ENT (29)
  • Environmental allergy and climate change (31)
  • Eosinophilic esophagitis (21)
  • Epidemiology (66)
  • Epithelial cell biology (8)
  • Food allergy (195)
  • Genomics and proteomics (17)
  • Immune deficiencies and autoimmunity (80)
  • Immunomodulation and nutrition (13)
  • Infections (27)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (24)
  • Microbiome (9)
  • Occupational allergy (27)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (144)
  • Prevention (40)
  • Systems medicine (13)
Poster available until
  • Until platform closure (46)
Poster categories
  • e-Thematic Poster Session (93)
  • Thematic Poster Session (980)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (14)
  • L-TPS17 (13)
  • L-TPS18 (10)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (12)
  • TPS52 (14)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (13)
  • TPS56 (16)
  • TPS57 (12)
  • TPS58 (12)
  • TPS59 (13)
  • TPS60 (14)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (8)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
1154 results
Thumbnail

D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent

Thumbnail

D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution

Thumbnail

D3.406 - Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients

Thumbnail

D3.407 - Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece

Thumbnail

D3.409 - Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment

Thumbnail

D3.410 - A concurrence of eosinophilic esophagitis and eosinophilic gastritis in a patient with hypereosinophillia

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"

Thumbnail

D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists

Thumbnail

D3.420 - IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas

Thumbnail

D3.422 - Evaluating Elevated Baseline Mast Cell Tryptase: Insights from an Adult Allergy Service

Thumbnail

D3.424 - Long-term efficacy and re-sting outcomes following venom immunotherapy discontinuation: A 978-patient analysis

Thumbnail

D3.425 - Anaphylactic reaction to carpenter bee

Thumbnail

D3.426 - The Frequency of Previous Large Local Reactions in a Group of 158 Patients with a History of Systemic Reaction after Insect Sting

Thumbnail

D3.427 - Current practices in diagnosis and treatment of Hymenoptera venom allergy (HVA) in Poland

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Current page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • …
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM